Our Mission
Improve patient care by developing molecular diagnostics that translate an individual's immune status into clinically actionable information.
About XDx
Founded in 2000, XDx is a molecular diagnostics company based in Brisbane, Calif. Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company has developed a proprietary new method for noninvasively monitoring the immune system by measuring gene expression in a patient’s peripheral blood. The technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering, immune-mediated diseases.
This work is the basis for AlloMap ® molecular expression testing, a service provided by XDx through its clinical laboratory in Brisbane, California. AlloMap testing provides transplant physicians a new tool for post-cardiac transplant patient management. The lab received CLIA (Clinical Laboratory Improvements Amendments) certification in November, 2004. AlloMap testing is being incorporated into clinical practice at leading U.S. cardiac transplant centers.
The AlloMap molecular expression technology developed and implemented by XDx in heart transplant patient management may be broadly applicable to other diseases that involve the immune system. XDx is applying its AlloMap testing experience for the development of a lung transplant rejection monitoring test through the LARGO study. XDx also foresees opportunities in common autoimmune and chronic inflammatory diseases that involve activation or dysfunction of the immune system.
